Artificial Intelligence in Oncology Drug Discovery and Development
There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic bur...
Saved in:
| Other Authors: | , |
|---|---|
| Format: | Electronic Book Chapter |
| Language: | English |
| Published: |
IntechOpen
2020
|
| Subjects: | |
| Online Access: | DOAB: download the publication DOAB: description of the publication |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000naaaa2200000uu 4500 | ||
|---|---|---|---|
| 001 | doab_20_500_12854_67655 | ||
| 005 | 20210420 | ||
| 003 | oapen | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 20210420s2020 xx |||||o ||| 0|eng d | ||
| 020 | |a intechopen.88376 | ||
| 020 | |a 9781789858976 | ||
| 020 | |a 9781789846898 | ||
| 020 | |a 9781789858983 | ||
| 040 | |a oapen |c oapen | ||
| 024 | 7 | |a 10.5772/intechopen.88376 |c doi | |
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a MBDC |2 bicssc | |
| 100 | 1 | |a Cassidy, John W. |4 edt | |
| 700 | 1 | |a Taylor, Belle |4 edt | |
| 700 | 1 | |a Cassidy, John W. |4 oth | |
| 700 | 1 | |a Taylor, Belle |4 oth | |
| 245 | 1 | 0 | |a Artificial Intelligence in Oncology Drug Discovery and Development |
| 260 | |b IntechOpen |c 2020 | ||
| 300 | |a 1 electronic resource (192 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
| 520 | |a There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by-nc/4.0/ |2 cc |4 https://creativecommons.org/licenses/by-nc/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medical ethics & professional conduct |2 bicssc | |
| 653 | |a Medical bioinformatics | ||
| 856 | 4 | 0 | |a www.oapen.org |u https://mts.intechopen.com/storage/books/10107/authors_book/authors_book.pdf |7 0 |z DOAB: download the publication |
| 856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/67655 |7 0 |z DOAB: description of the publication |